UY33236A - Inhibidores dimericos de las iap - Google Patents

Inhibidores dimericos de las iap

Info

Publication number
UY33236A
UY33236A UY0001033236A UY33236A UY33236A UY 33236 A UY33236 A UY 33236A UY 0001033236 A UY0001033236 A UY 0001033236A UY 33236 A UY33236 A UY 33236A UY 33236 A UY33236 A UY 33236A
Authority
UY
Uruguay
Prior art keywords
iap
dimeric
dimeric inhibitors
formula
inhibitors
Prior art date
Application number
UY0001033236A
Other languages
English (en)
Inventor
Christopher Sean Straub
Chen Zhuoliang
Mark G Palermo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33236A publication Critical patent/UY33236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Abstract

El presente invento proporciona compuestos de la fórmula M-L-M´(donde M y M´ son cada uno, de manera independiente, una fracción monomérica de la fórmula (I) y L es un enlazador). Se ha encontrado que los compuestos diméricos son efectivos para promover la apoptosis en células que se estén dividiendo rápidamente.
UY0001033236A 2010-02-25 2011-02-21 Inhibidores dimericos de las iap UY33236A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US33392710P 2010-05-12 2010-05-12
US38841010P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
UY33236A true UY33236A (es) 2011-09-30

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033236A UY33236A (es) 2010-02-25 2011-02-21 Inhibidores dimericos de las iap

Country Status (13)

Country Link
US (1) US8445440B2 (es)
EP (1) EP2539333A1 (es)
JP (1) JP2013520466A (es)
KR (1) KR20130010894A (es)
CN (1) CN102834389A (es)
AR (1) AR080253A1 (es)
BR (1) BR112012021291A2 (es)
CA (1) CA2790302A1 (es)
EA (1) EA201201177A1 (es)
MX (1) MX2012009894A (es)
TW (1) TW201141846A (es)
UY (1) UY33236A (es)
WO (1) WO2011104266A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
WO2014025759A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
WO2014074658A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Macrocyclic compounds for inhibition of inhibitors of apoptosis
EA036275B1 (ru) 2013-06-25 2020-10-21 Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч Способ лечения внутриклеточной инфекции
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
ATE481092T1 (de) 2002-11-27 2010-10-15 Irm Llc Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20110251134A1 (en) 2004-02-05 2011-10-13 Leigh Zawel Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
CA2582734C (en) * 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007021825A2 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
BRPI0617751A2 (pt) * 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
ES2684120T3 (es) * 2005-12-20 2018-10-01 Novartis Ag Combinación de un inhibidor de IAP y un taxano
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
WO2007136921A2 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2008014252A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
EP2076778A2 (en) * 2006-10-19 2009-07-08 Novartis AG Organic compounds
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008085610A1 (en) 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
AU2008240153B2 (en) * 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
US20110008802A1 (en) 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
PE20140100A1 (es) 2007-09-12 2014-02-12 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
MX2010007543A (es) 2008-01-11 2010-09-30 Genentech Inc Inhibidores de iap.
AU2009206588A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CA2728933A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2010033531A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
CA2737280A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Also Published As

Publication number Publication date
EA201201177A1 (ru) 2013-04-30
CN102834389A (zh) 2012-12-19
WO2011104266A1 (en) 2011-09-01
AU2011219862A1 (en) 2012-09-06
MX2012009894A (es) 2012-09-12
AR080253A1 (es) 2012-03-21
KR20130010894A (ko) 2013-01-29
CA2790302A1 (en) 2011-09-01
US20110206690A1 (en) 2011-08-25
EP2539333A1 (en) 2013-01-02
BR112012021291A2 (pt) 2016-10-25
TW201141846A (en) 2011-12-01
US8445440B2 (en) 2013-05-21
JP2013520466A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
UY33794A (es) Inhibidores diméricos de las iap
UY33236A (es) Inhibidores dimericos de las iap
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
ECSP13013074A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140464A (es) Compuestos de heterociclilo
CR20150250A (es) Nuevos derivados de piridina
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CU20140025A7 (es) Pirimidinas anilladas sustituidas
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CR20150204A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150447A (es) Nuevos derivados de pirazol
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
TR201908180T4 (tr) N1-asil- 5-floropirimidinon deriveleri.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200616